Roxbury Financial’s Anavex Life Sciences AVXL Stock Holding History

Roxbury Financial’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-580	Closed	-$4.59K	–	364
2025 Q1	$4.59K	Hold	580	–	–	﹤0.01%	302
2024 Q4	$5.49K	Buy	+580	New	+$4.46K	0.01%	324

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Roxbury Financial's AVXL Position: Q2 2025 in Review

Roxbury Financial sold out of Anavex Life Sciences (AVXL) in Q2 2025, closing a stake of 580 shares — an estimated $4.59K sold.

Roxbury Financial first reported a position in AVXL in Q4 2024 and held it in 2 quarters. The position peaked at $5.49K in Q4 2024. 178 funds tracked by Wall St. Rank hold AVXL as of Q2 2025.

Roxbury Financial reported no remaining Anavex Life Sciences position as of Q2 2025 after selling out during the quarter.
Roxbury Financial sold 580 Anavex Life Sciences shares in Q2 2025, an estimated $4.59K.
Roxbury Financial first reported a position in Anavex Life Sciences in Q4 2024 and held it in 2 quarters.
Roxbury Financial's Anavex Life Sciences position peaked at $5.49K in Q4 2024.
178 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2025.

Based on Roxbury Financial's 13F filing for Q2 2025, filed 7 Jul 2025.